Table 1 Clinical characteristics of patients with NSCLC (adenocarcinoma) and healthy donors (HD) enrolled in our study.

N/A, not applicable.

Patient
number
GenderAge (years)Smoking
history
(years)
Tumor gradeClinical
stage
CTC counts*ALK/
ROS1
status
(tissue)
ALK/
ROS1
status
(CTCs)
Copy numbers of
ALK/ROS1
rearrangements
in CTCs*
A01Male53None3IV18EML4-ALKEML4-ALK333
A02Male38None3IV15EML4-ALKEML4-ALK603
A03Male65None3IV32EML4-ALKEML4-ALK198
A04Female65None3IV27EML4-ALKEML4-ALK1728
A05Male53None3IV16EML4-ALKEML4-ALK252
A06Male58None3IV26EML4-ALKEML4-ALK207
A07-1Male39None2IV15EML4-ALKEML4-ALK108
A07-2Male39None2IV11EML4-ALKEML4-ALK81
A07-3Male39None2IV9EML4-ALKEML4-ALK54
A07-4Male39None2IV0EML4-ALKEML4-ALK0
A07-5Male39None2IV0EML4-ALKEML4-ALK0
R01Female62None3IIIB28CD74-ROS1CD74-ROS1504
R02Male41None2IIIB22CD74-ROS1CD74-ROS1594
R03Male61352IV17CD74-ROS1CD74-ROS1684
R04Male34None3IV27CD74-ROS1CD74-ROS1963
R05-1Male32None3IV28CD74-ROS1CD74-ROS11773
R05-2Male32None3IV6CD74-ROS1CD74-ROS1162
R05-3Male32None3IV36CD74-ROS1CD74-ROS12061
HD01Male30NoneN/AN/A0N/AN/A0
HD02Male26NoneN/AN/A0N/AN/A0
HD03Male29NoneN/AN/A0N/AN/A0
HD04Male46NoneN/AN/A0N/AN/A0
HD05Female36NoneN/AN/A0N/AN/A0
HD06Male32NoneN/AN/A0N/AN/A0

*Per 2 ml of blood.